FX-111 / Flare Therap - LARVOL DELTA

Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer (AACR 2026) - "Targeting ARON in PC could potentially treat all forms of PC that are driven by AR signaling without the need for androgen deprivation. FX-111 is currently in IND-enabling studies with plans to initiate clinical studies in 2026."

Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • CRBN

AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC) (AACR 2026) - "From the Caris Prostate Cancer Database (N=17,429), 511 mCRPC patients treated with ARSI (Abiraterone and/or Enzalutamide) were identified. FX-111, a selective degrader of transcriptionally active, hormone-bound AR (ARON) in IND-enabling studies by Flare Therapeutics, offers a promising strategy to address this resistance. Ongoing analyses of AR/KLK3 subgroups aim to elucidate biological drivers of differential ARSI response."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KLK3